Selective intrauterine growth restriction
suh-lek-tiv in-truh-yoo-ter-in growth ri-strik-shun
Also known as: SIUGR, Selective fetal growth restriction
At a Glance
What is Selective intrauterine growth restriction?
Selective intrauterine growth restriction (SIUGR) is a condition that affects twin pregnancies, specifically monochorionic twins who share a placenta. It occurs when one twin receives less blood flow than the other, leading to unequal growth. The condition primarily affects the fetal development system, impacting the smaller twin's growth and overall health. SIUGR can be caused by unequal placental sharing or placental insufficiency. Over time, the growth disparity between the twins may increase, potentially leading to complications. Early symptoms might not be noticeable, but as the pregnancy progresses, one twin may show signs of restricted growth. Early diagnosis is crucial to manage the condition and prevent severe outcomes like fetal demise. The condition can be stressful for families, requiring frequent monitoring and potential interventions. The prognosis varies; some twins may catch up in growth after birth, while others may face long-term health challenges. Daily life for affected families often involves regular medical check-ups and potential interventions. With appropriate management, many affected twins can have positive outcomes. However, the condition requires careful monitoring to ensure the best possible health for both twins.
Medical Definition
Selective intrauterine growth restriction (SIUGR) is characterized by a significant size discrepancy between fetuses in monochorionic twin pregnancies due to unequal placental sharing. Pathologically, it involves impaired placental perfusion leading to fetal hypoxia and nutrient deficiency. Histological findings may reveal placental vascular abnormalities. SIUGR is classified into types based on umbilical artery Doppler studies, which guide management strategies. Epidemiologically, it occurs in approximately 10-15% of monochorionic twin pregnancies. The disease course can vary, with potential outcomes ranging from intrauterine fetal demise to postnatal catch-up growth, depending on the severity and management of the condition.
Selective intrauterine growth restriction Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Asymmetric fetal growth manifests as a significant size difference between twins, with one twin being smaller. This occurs due to unequal placental sharing, leading to restricted nutrient and oxygen supply to the smaller twin. Over time, the growth disparity may increase, potentially leading to complications such as fetal distress. Daily life is affected as it requires frequent monitoring and possibly interventions such as increased prenatal visits and dietary adjustments.
Oligohydramnios is characterized by a reduced amount of amniotic fluid surrounding the smaller twin. It results from impaired placental function, which affects the twin's ability to produce urine, a major component of amniotic fluid. This condition can worsen over time, increasing the risk of compression and developmental issues. Management includes close monitoring and possibly amnioinfusion to increase fluid levels.
Abnormal Doppler studies indicate altered blood flow patterns in the umbilical artery of the smaller twin. These changes are due to increased resistance in the placental circulation, reflecting compromised blood supply. Over time, persistent abnormalities can lead to fetal hypoxia and growth restriction. Regular Doppler assessments are crucial for monitoring and guiding clinical decisions to optimize outcomes.
Common
Fetal distress is a condition where the smaller twin shows signs of compromised well-being, such as abnormal heart rate patterns. It is caused by inadequate oxygen and nutrient delivery due to placental insufficiency. Without intervention, fetal distress can progress to more severe complications, including stillbirth. Management involves close surveillance and timely delivery if necessary to prevent adverse outcomes.
Reduced fetal movements are observed as decreased activity of the smaller twin in the womb. This symptom arises from limited energy reserves and potential hypoxia affecting the twin's vitality. Over time, persistent reduction in movements can indicate worsening fetal condition. Monitoring fetal movements and conducting non-stress tests can help assess fetal health and guide interventions.
Polyhydramnios in the larger twin is characterized by an excessive amount of amniotic fluid. This occurs due to increased urine production as a compensatory mechanism for the smaller twin's reduced fluid. If left unchecked, polyhydramnios can lead to preterm labor and maternal discomfort. Management may include amnioreduction and careful monitoring to prevent complications.
Less Common
Preterm labor involves the onset of labor before 37 weeks of gestation, often triggered by complications from growth restriction. The stress on the uterus from unequal fluid levels and fetal size can initiate contractions. If not managed, preterm labor can result in premature delivery and associated neonatal risks. Preventive measures include medications to delay labor and corticosteroids to enhance fetal lung maturity.
Fetal anemia is a condition where the smaller twin has a reduced red blood cell count, leading to insufficient oxygen transport. This can occur due to placental insufficiency affecting erythropoiesis. Over time, anemia can exacerbate growth restriction and increase the risk of fetal compromise. Treatment may involve intrauterine transfusions to correct anemia and improve outcomes.
What Causes Selective intrauterine growth restriction?
Selective intrauterine growth restriction (SIUGR) is not typically associated with specific gene mutations but rather with vascular and placental factors. In monochorionic diamniotic twin pregnancies, unequal placental sharing is a primary cause, where one twin receives less blood supply. The imbalance in blood flow can lead to hypoxia and nutrient deficiency for the affected twin. This condition does not involve a single gene mutation but rather the placental vascular anastomoses that disrupt normal blood distribution. The immediate molecular consequence is reduced oxygen and nutrient delivery to the fetus, leading to impaired fetal growth. This results in dysfunction of cellular metabolism and energy production within the affected twin's cells. Neighboring cells and tissues experience stress due to the lack of essential nutrients, leading to potential organ damage. The immune response may be triggered by tissue hypoxia, contributing to inflammation. Neuroinflammation can occur as the brain is particularly sensitive to oxygen deprivation. White matter development may be compromised, leading to potential neurodevelopmental issues. Symptoms appear as growth restriction and potential neurological deficits due to the specific organs affected by nutrient deprivation. Disease severity varies depending on the degree of placental sharing and the presence of compensatory mechanisms. Some twins may develop adaptive responses that mitigate the effects of nutrient restriction. In severe cases, the affected twin may experience significant growth restriction or even fetal demise. The variability in outcomes is influenced by the extent of placental vascular connections and the timing of intervention.
How is Selective intrauterine growth restriction Diagnosed?
Typical age of diagnosis: Selective intrauterine growth restriction is typically diagnosed during the second trimester of pregnancy, often between 18 to 24 weeks gestation, when routine ultrasound screenings are performed.
Clinicians assess maternal history for risk factors such as previous pregnancy complications and maternal health conditions. The physical examination may reveal discrepancies in fundal height measurements compared to gestational age. This step helps identify pregnancies at risk for growth abnormalities. It sets the stage for further diagnostic imaging to confirm the presence of selective intrauterine growth restriction.
Ultrasound is the primary imaging modality used to diagnose selective intrauterine growth restriction. It reveals discrepancies in fetal size, particularly in monochorionic diamniotic twin pregnancies. Findings such as discordant fetal growth and abnormal Doppler flow patterns confirm the diagnosis. Imaging helps exclude other conditions like twin-to-twin transfusion syndrome.
Specific laboratory tests may include maternal serum markers such as alpha-fetoprotein and placental growth factor. Abnormal levels of these biomarkers can indicate placental dysfunction. These results help guide further management decisions and assess the risk of adverse outcomes. However, laboratory tests are supplementary and not definitive for diagnosis.
Genetic testing may involve sequencing genes associated with fetal growth and placental function. Mutations in genes like IGF1R or placental growth factor genes may be identified. Results can confirm a genetic basis for the growth restriction and guide genetic counseling. This information is crucial for family planning and assessing recurrence risk in future pregnancies.
Selective intrauterine growth restriction Treatment Options
Aspirin is an antiplatelet agent that may improve placental blood flow. It is used in low doses to reduce the risk of preeclampsia and improve fetal outcomes. Clinical evidence suggests it may benefit pregnancies at risk for growth restriction. However, its efficacy specifically for selective intrauterine growth restriction is not well-established. Side effects include gastrointestinal discomfort and bleeding risks.
Techniques include maternal rest in a left lateral position to improve uteroplacental blood flow. The goal is to enhance fetal growth by optimizing maternal circulation. Sessions may involve daily rest periods of several hours. Measurable outcomes include improved fetal growth parameters on ultrasound. Long-term benefits may include reduced risk of preterm birth and improved neonatal outcomes.
Indicated for severe cases with significant discordance in twin growth and abnormal Doppler studies. The procedure involves coagulating placental anastomoses to equalize blood flow between twins. Expected benefits include improved growth of the smaller twin and reduced risk of fetal demise. Surgical risks include preterm labor and membrane rupture. Post-operative care requires close monitoring of fetal growth and well-being.
The care team includes obstetricians, neonatologists, and maternal-fetal medicine specialists. Interventions focus on monitoring fetal growth, maternal health, and planning delivery timing. Psychosocial support includes counseling for stress management and coping strategies. Family education involves understanding the condition and potential outcomes. Long-term monitoring plans ensure early detection of complications and timely interventions.
When to See a Doctor for Selective intrauterine growth restriction
- Severe abdominal pain — this could indicate a complication such as placental abruption, which requires immediate medical attention.
- Heavy vaginal bleeding — this may signal a serious issue like placental abruption or preterm labor, necessitating urgent care.
- Sudden decrease in fetal movements — this could be a sign of fetal distress or demise, requiring prompt evaluation by a healthcare provider.
- Persistent mild abdominal pain — could indicate uterine contractions or other issues; consult your doctor for evaluation.
- Unusual swelling of hands or face — may be a sign of preeclampsia, which needs medical assessment.
- Consistent headaches or visual disturbances — these symptoms could be associated with high blood pressure and should be discussed with a healthcare provider.
- Mild backache — common in pregnancy; monitor for worsening or persistence and use home remedies like rest and heat application.
- Occasional mild cramping — often normal, but keep track of frequency and intensity, and consult a doctor if they increase.
Selective intrauterine growth restriction — Frequently Asked Questions
Is this condition hereditary?
Selective intrauterine growth restriction is not typically hereditary. The condition is more related to placental issues rather than genetic inheritance. De novo mutations are not a common cause of this condition. Carrier status is not applicable as it is not a genetic disorder. Genetic counseling is generally not necessary unless other genetic conditions are suspected.
What is the life expectancy for someone with this condition?
Life expectancy can vary significantly depending on the severity and management of the condition. Early diagnosis and intervention can improve outcomes. Mortality is often related to complications such as preterm birth or fetal demise. Treatment and monitoring can significantly enhance survival rates. Realistic expectations should include close monitoring and potential interventions to optimize fetal health.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis typically involves ultrasound imaging to assess fetal growth patterns. The time from first symptoms to diagnosis can vary, often depending on the frequency of prenatal visits. Obstetricians and maternal-fetal medicine specialists are usually involved in the diagnostic process. Delays in diagnosis may occur if symptoms are mild or not immediately apparent. Confirmation is achieved through detailed ultrasound findings and growth assessments.
Are there any new treatments or clinical trials available?
Research is ongoing into novel therapies, including improved surgical techniques and placental interventions. Gene therapy is not applicable, but other innovative approaches are being explored. ClinicalTrials.gov is a resource for finding relevant clinical trials. Discuss with your doctor about eligibility and potential benefits of participating in trials. New treatments may take several years to become widely available, depending on trial outcomes.
How does this condition affect daily life and activities?
The condition primarily affects the pregnancy rather than daily life directly. It may require more frequent medical appointments and monitoring. Emotional and social challenges can arise due to anxiety about fetal health. Family burden may increase due to the need for additional care and support. Supportive resources and adaptations, such as counseling and educational materials, can be beneficial.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Selective intrauterine growth restriction without concomitant twin-to-twin transfusion syndrome, natural history, and risk factors for fetal death: A systematic review and meta-analysis.
Mustafa HJ, Javinani A, Heydari MH et al. · Am J Obstet Gynecol MFM · 2023 · PMID: 37527736
- 2.Selective intrauterine growth restriction in monochorionic diamniotic twin pregnancies.
Bennasar M, Eixarch E, Martinez JM et al. · Semin Fetal Neonatal Med · 2017 · PMID: 28532678
- 3.Selective intrauterine growth restriction of monochorionic diamniotic twin pregnancies: What is the neonatal prognosis?
Gremillet L, Netter A, Tosello B et al. · J Gynecol Obstet Hum Reprod · 2022 · PMID: 34974148
- 4.Selective intrauterine growth restriction (SIUGR) type II: proposed subclassification to guide surgical management.
Chmait RH, Chon AH, Korst LM et al. · J Matern Fetal Neonatal Med · 2022 · PMID: 32233709
- 5.Selective intrauterine growth restriction in monochorionic diamniotic twin pregnancies.
Valsky DV, Eixarch E, Martinez JM et al. · Prenat Diagn · 2010 · PMID: 20661884
- 6.Selective intrauterine growth restriction in monochorionic twins: pathophysiology, diagnostic approach and management dilemmas.
Valsky DV, Eixarch E, Martinez JM et al. · Semin Fetal Neonatal Med · 2010 · PMID: 20675206
- 7.Selective fetal growth restriction type II: IIb or not IIb.
Youssefzadeh AC, Chmait RH · Am J Obstet Gynecol MFM · 2026 · PMID: 41205811
- 8.Management and perinatal outcome of selective intrauterine growth restriction in monochorionic pregnancies.
Sukhwani M, Antolín E, Herrero B et al. · J Matern Fetal Neonatal Med · 2021 · PMID: 31766901
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-05-24